Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection
Angiotensin-converting enzyme 2 (ACE2), the host cell-binding site for SAR-CoV-2, poses two-fold drug development problems. First, the role of ACE2 itself is still a matter of investigation, and no specific drugs are available targeting ACE2. Second, as a consequence of SARS-CoV-2 interaction with A...
Main Author: | Ramesh K. Goyal, Jaseela Majeed, Rajiv Tonk, Mahaveer Dhobi, Bhoomika Patel, Kalicharan Sharma, Subbu Apparsundaram |
---|---|
Format: | Article |
Language: | English |
Published: |
IMR (Innovative Medical Research) Press Limited
2020-09-01
|
Series: | Reviews in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://rcm.imrpress.com/fileup/2153-8174/PDF/1601436628011-1720097959.pdf |
Similar Items
-
In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19
by: Divya M. Teli, et al.
Published: (2021-01-01) -
Data on the docking of phytoconstituents of betel plant and matcha green tea on SARS-CoV-2
by: Fatimawali, et al.
Published: (2021-06-01) -
Indian Herb-Derived Phytoconstituent-Based Antiviral, Antimicrobial and Antifungal Formulation: An Oral Rinse Candidate for Oral Hygiene and the Potential Prevention of COVID-19 Outbreaks
by: Shashwat Sharad, et al.
Published: (2021-09-01) -
Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study
by: Abd-ElAziem Farouk, et al.
Published: (2021-06-01) -
Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug
by: Fuad Ameen, et al.
Published: (2021-10-01)